Ocular Therapeutix Inc
Statements
Cash Flow
Ocular Therapeutix Inc (OCUL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -67 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.3 | -7.6 | -15 | -11 | -14 | -10 | -12 | -12 | -11 | -14 | -19 | -19 | -20 | -19 | -19 | -15 | -14 | -6.2 | -17 | -20 | -13 | -15 | -19 | -11 | -13 | -17 | -20 | -20 | -13 | -22 | -34 | -25 | -37 | -39 | -45 | -55 | -51 | -54 | -66 | -67 | -238 | |
| 0.2 | 0.3 | 0.3 | 0.4 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.6 | 0.8 | 0.4 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | 0.7 | 0.9 | 1.0 | 0.9 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.1 | 1.2 | 1.3 | 1.9 | 5.5 | |
| 1.4 | 1.7 | 1.7 | 1.8 | 1.8 | 2.1 | 1.8 | 1.8 | 1.9 | 1.9 | 1.9 | 1.7 | 3.2 | 2.0 | 1.7 | 1.8 | 1.9 | 2.1 | 3.1 | 4.3 | 3.8 | 3.8 | 4.2 | 4.3 | 4.2 | 4.2 | 4.6 | 4.4 | 4.5 | 4.3 | 8.0 | 11 | 6.6 | 7.2 | 10 | 9.7 | 12 | 11 | 16 | 15 | 53 | |
| 1.4 | 3.0 | 1.7 | 1.8 | 1.7 | 2.1 | 1.8 | 1.8 | 1.9 | 1.9 | -1.3 | 3.3 | -2.5 | 5.0 | 5.1 | 19 | -1.8 | 72 | -22 | -8.0 | -19 | -11 | -2.7 | 2.7 | 5.4 | -1.0 | 11 | 3.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.6 | 1.7 | -0.6 | 5.3 | -1.1 | 0.0 | -1.2 | -0.9 | 1.6 | 1.1 | -2.2 | 0.2 | 0.4 | -0.3 | -4.2 | 1.1 | -1.7 | 5.9 | -0.3 | -4.2 | 2.7 | -1.0 | -5.1 | 4.6 | 3.9 | -2.1 | -2.5 | -4.6 | 6.2 | -6.6 | -13 | 3.1 | -1.2 | 0.9 | 5.5 | 0.6 | 3.7 | -2.1 | 1.0 | -5.0 | -2.4 | |
| 0.9 | 0.7 | 1.7 | 4.0 | 2.0 | 0.6 | 0.4 | 0.6 | 0.5 | 0.5 | 0.7 | 0.5 | 0.4 | 0.6 | 0.2 | 0.1 | 0.2 | 0.3 | 0.2 | 0.1 | 0.3 | 0.6 | 0.3 | 0.5 | 0.8 | 2.2 | 3.4 | 2.0 | 0.3 | 0.5 | 0.3 | 0.7 | 0.1 | 0.2 | 1.9 | 1.2 | 6.0 | 2.8 | 4.7 | 3.4 | 17 | |
| 11 | -12 | 7.8 | 19 | 1.0 | -0.5 | -0.4 | -0.6 | -0.5 | -0.5 | -0.7 | -0.5 | -0.4 | -0.6 | -0.2 | -0.1 | -0.2 | -0.3 | -0.2 | -0.1 | -0.3 | -0.6 | -0.3 | -0.5 | -0.8 | -2.2 | -3.4 | -2.0 | -0.3 | -0.5 | -0.3 | -0.7 | -0.1 | -0.2 | -1.9 | -1.1 | -6.0 | -2.8 | -4.7 | -3.4 | -17 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | 0.0 | 0.3 | – | – | – | – | – | – | – | – | 1.5 | – | – | 0.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.1 | 0.3 | 26 | 1.0 | 1.7 | 0.3 | 35 | 8.3 | 13 | 0.3 | 5.0 | 5.4 | 19 | 0.5 | 13 | 51 | 0.2 | 0.7 | -0.3 | 1.0 | 0.7 | 1.3 | 0.1 | 0.5 | 0.4 | 0.9 | 0.1 | 9.6 | – | 0.9 | – | – | 0.5 | – | – | 0.7 | – | – | – | 0.9 | – | |
| -0.1 | 2.4 | 2.4 | -1.0 | -1.0 | 2.4 | -1.0 | -1.5 | -1.5 | 10 | 37 | -0.1 | – | – | – | -2.1 | -2.1 | -2.1 | -2.1 | 1.6 | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | |
| 0.1 | 0.7 | 28 | 0.8 | 1.5 | 1.2 | 34 | 6.7 | 11 | 16 | 42 | 5.3 | 19 | 9.1 | 13 | 51 | 0.2 | 164 | -1.2 | 2.7 | 0.7 | 0.7 | 0.1 | 0.5 | 0.4 | 0.5 | 0.1 | 9.6 | 57 | 108 | 321 | 2.2 | 4.2 | 4.5 | 4.2 | 98 | 10 | 449 | 0.3 | 2.6 | 463 | |
| 4.1 | -19 | 22 | 8.4 | -12 | -9.6 | 21 | -6.1 | 0.0 | 2.2 | 22 | -14 | -1.4 | -11 | -6.3 | 36 | -14 | 157 | -19 | -18 | -13 | -15 | -19 | -11 | -14 | -19 | -23 | -12 | 44 | 85 | 287 | -23 | -32 | -35 | -42 | 41 | -46 | 392 | -70 | -68 | 208 | |
| -8.2 | -8.3 | -16 | -15 | -16 | -11 | -13 | -13 | -11 | -14 | -20 | -20 | -20 | -20 | -19 | -15 | -14 | -6.5 | -18 | -20 | -13 | -16 | -19 | -11 | -14 | -19 | -23 | -22 | -13 | -23 | -34 | -26 | -37 | -40 | -47 | -56 | -57 | -57 | -71 | -71 | -255 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.